Primary progressive aphasia (PPA) is a rare neurological syndrome that gradually impairs a person’s language. Baycrest Canada ...

A study has developed a reliable way to measure whether seriously ill hospitalized patients receive medical care that aligns ...

The CEO of GH Research, Dr. Velichka Valcheva, pointed out that the response addressed the FDA’s requests with comprehensive ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

Rahway, New Jersey Wednesday, July 9, 2025, 13:00 Hrs [IST] ...

Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes ...

John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid, with ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...